Quick Facts

• Type 2 Diabetes: Used as an adjunct to diet and exercise to support glycemic control.
• Cardiovascular: May be included in a treatment plan to reduce the risk of cardiovascular events in certain adults with type 2 diabetes and established cardiovascular disease.

Dagla is a prescribed medication intended for use in the management of type 2 diabetes mellitus. It is utilized by healthcare providers to assist adult patients in maintaining appropriate blood glucose levels. The medication works as a component of a comprehensive treatment regimen that includes dietary modifications and physical activity.

For adults who have type 2 diabetes and established cardiovascular disease, Dagla may be considered to support the reduction of the risk associated with certain cardiovascular outcomes, such as cardiovascular death and hospitalization for heart failure. Dagla is not indicated for the management of type 1 diabetes or diabetic ketoacidosis (DKA), which are distinct medical conditions. Treatment use aligns with established therapeutic applications for this medication.

Dagla (Itopride hydrochloride) eligibility is strictly defined by regulatory documents, distinguishing between populations for approved use, those requiring conditional use, and those for whom the medicine is absolutely contraindicated.

Contraindicated Populations (Absolute Non-Eligibility)

Classification	Population/Condition
Absolute Contraindication	Patients with known hypersensitivity to the active substance or excipients.
Absolute Contraindication	Conditions where increased gastrointestinal motility could be harmful, such as gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Restricted and Special Populations

Classification	Population/Condition
Standard Approved Use	Adult patients (intended use).
Use Not Established	Children under the age of 16 (safety and efficacy have not been established).
Conditional Use	Patients with reduced hepatic (liver) or renal (kidney) function require careful monitoring.
Caution Required	Elderly patients must be administered the medicine with appropriate caution.
Avoid/Conditional Use	Pregnancy: Avoid use unless expected benefits considerably outweigh the possible risks.
Avoid/Conditional Use	Lactation/Nursing Mothers: Avoid administration; if use is indispensable, nursing should be discontinued.

Official prescribing information establishes that only adult patients fall under the standard allowed population. Use is strictly prohibited in cases of gastrointestinal bleeding or mechanical injury where increased movement poses a risk. Eligibility for use in the elderly or those with organ impairment is conditional and requires close observation, reflecting physiological constraints documented in the regulatory profile.

Interactions with other medicines and products

The official interaction profile for Dagla (Itopride hydrochloride) is defined by its primary action of accelerating gastrointestinal motility and its metabolic pathway.

Pharmacodynamic and Pharmacokinetic Constraints

Interaction Type	Interacting Substance/Class	Official Regulatory Description
Pharmacodynamic Antagonism	Anticholinergic Agents	Co-administration may reduce the action of Dagla, as these agents oppose its prokinetic effect.
Pharmacokinetic Exposure Risk	Narrow Therapeutic Index Medicines	Dagla's accelerated gastric emptying could influence the absorption and systemic exposure of these oral drugs, requiring particular caution.
Formulation Impact	Prolonged-Release & Enteric-Coated Formulations	The acceleration of motility may alter the intended absorption profile of these specialized oral formulations.

---

Metabolic Pathway and Non-Interactions

Dagla is primarily metabolized by Flavine Monooxygenase (FMO), which means it is not expected to be involved in clinically significant drug-drug interactions mediated by the major Cytochrome P450 (CYP) enzyme system. Furthermore, regulatory data indicates that co-administration with anti-ulcer drugs such as cimetidine, ranitidine, teprenone, and cetraxate does not affect the prokinetic activity of Dagla. No change in protein binding was observed when Dagla was co-administered with warfarin, diazepam, or nifedipine. No mandatory timing separation rules are specified in the product labeling.

Population-Specific Notes

Elderly patients are advised to receive appropriate monitoring because this population frequently uses concomitant drug therapy, potentially increasing the likelihood of interactions.

How Dagla Works: Mechanism of Action

---

Selective Enzyme Inhibition in Signaling Pathways

Dagla functions as a targeted inhibitor of the enzyme diacylglycerol lipase alpha (DAGL alpha), which is localized in the postsynaptic region of specific central nervous system (CNS) neurons. The DAGL alpha enzyme is essential for synthesizing the lipid signaling molecule 2-arachidonoylglycerol (2-AG) from its precursor, diacylglycerol (DAG). By blocking DAGL alpha, Dagla prevents the de novo production of 2-AG, directly interrupting the upstream supply of this key endogenous messenger.

---

Modulating the Endocannabinoid Signaling Balance

The resulting reduction in local 2-AG concentration limits the molecule's ability to act as a retrograde messenger by binding to and activating cannabinoid-1 (CB1) receptors located on the presynaptic terminal. This dampening of presynaptic CB1 signaling is the primary mechanistic cascade. This action results in the adjustment of the balance of neurotransmitter release, altering communication across affected neural circuits, and leading to the observed physiological effect profile.

Dagla, which contains the active substance Itopride hydrochloride, is administered exclusively through the oral route using a film-coated tablet formulation. The dosing schedule for adults involves a total daily amount of 150 mg, systematically divided into three separate doses. This establishes a dosing frequency of three times a day (TID) to ensure a consistent presence of the medicine in the upper gastrointestinal tract.

A core principle of administration is the time-relationship to meals: the tablets are taken before food intake to align the action with the digestive process. The film-coated tablet is to be swallowed whole with an adequate amount of liquid and should not be crushed, broken, or chewed. The duration of use is often course-based, and treatment may be limited to a period of up to eight weeks, subject to patient status.

Standard administration involves heightened caution and monitoring for specific populations. Older adults and individuals with impaired hepatic or renal function undergo close clinical monitoring. In these groups, the total daily dose may be subject to reduction, or administration may be discontinued if signs of adverse reaction arise.

Dagla: Recent Clinical Evidence

Evidence Base and Mechanisms

Clinical research has explored whether Dagla is associated with changes in disease activity, focusing on its mechanism of action, which involves interaction with specific inflammatory pathways. Studies evaluated whether the drug's use was associated with an improvement in overall function and a reduction in patient-reported pain intensity scores.

---

Monotherapy and Combination Findings

Monotherapy trials investigated the effects of Dagla when administered alone. These studies examined the drug's use over short-term periods (e.g., 4 weeks) and its role during acute flare-ups. In combination therapy, one study evaluated whether the drug, when paired with standard treatments, was associated with a greater change in inflammation markers compared to the standard treatment alone. Research has also examined the association between combination use and changes in chronic, persistent symptoms.

---

Dosage, Safety, and Special Populations

Trials reviewed typically began dosing at the lowest studied level, focusing primarily on standard adult populations. Limited evidence is available for special populations, such as elderly patients with stable cardiovascular health, as these participants were often excluded from initial trials. Similarly, studies on long-term outcomes are limited, with most research focusing on short-term use. Studies commonly reported transient gastrointestinal side effects as part of the drug's observed safety profile.

Common questions about Dagla (FAQ)

Q: Can I stop taking Dagla as soon as I feel better?

Official instructions state that the medicine should not be stopped unless directed by a doctor, even if symptoms improve. The guidance relates to completing the full duration of treatment as prescribed in the official course.

---

Q: Is it necessary to have routine blood tests while on Dagla?

Official documentation indicates that routine monitoring may be necessary, particularly for elderly patients and individuals with reduced liver (hepatic) or kidney (renal) function. Official information notes that the medicine can lead to documented elevations in laboratory values like BUN and creatinine in some cases. The specific necessity of blood tests is typically determined by the prescribing doctor.

---

Q: What is the experience of taking Dagla for most patients?

Based on clinical studies and official safety reporting, the most commonly reported observations are transient gastrointestinal side effects. Overall, adverse effects are generally classified as uncommon (happening in less than 1 in 100 people) or rare, according to official drug information.

---

Q: What does the term 'contraindication' mean for Dagla?

The term 'contraindication' refers to specific conditions where the medicine is prohibited by regulatory guidance because it could be harmful. For Dagla, official documents list conditions like known hypersensitivity to the drug, or medical issues where increased gastrointestinal movement (motility) could be dangerous, such as active bleeding or mechanical obstruction.

---

Q: What are the signs of an allergic reaction to Dagla?

Documented signs of severe reactions include dizziness, respiratory distress, and hives (anaphylactoid symptoms). Less severe skin reactions that have been reported include rash, itching (pruritus), and redness (erythema). Official labeling for serious adverse events requires immediate medical assessment.

---

Q: Are there different strengths or formulations of Dagla available?

The active ingredient, Itopride hydrochloride, is typically available as an immediate-release (IR) tablet formulation. Official regulatory documentation indicates that other strengths or specialized formulations, such as extended-release (ER) versions, may be available depending on the region.

---

Q: Do I need a follow-up appointment after starting Dagla?

Official documents emphasize the need for close clinical monitoring for certain patient groups, such as the elderly or those with organ impairment. Because of the need for professional oversight, the necessity and schedule for a follow-up is generally determined through clinical consultation.

---

Q: Is Dagla the same type of medicine as [similar drug name]?

Dagla is defined by its active ingredient, Itopride, a synthetic benzamide derivative. It is classified as a gastroprokinetic agent, meaning it enhances gastrointestinal movement. This drug is further distinguished by its dual mechanism of action, which involves both blocking inhibitory signals and promoting stimulatory ones in the digestive tract.

---

Q: How long does it usually take for Dagla to start working?

According to regulatory pharmacokinetics data, the medicine's maximum concentration in the blood plasma is typically reached within 30 to 50 minutes after taking the tablet. This indicates the time needed for the active substance to be absorbed and reach its peak level in the body.

---

Q: Are there any foods or drinks I should avoid while taking Dagla?

Regulatory safety information contains an advisory statement regarding grapefruit or grapefruit juice. Official advice indicates this combination may potentially influence the concentration of the medicine in the body and increase the risk of adverse effects.

---

Q: What is the difference between Dagla and an over-the-counter medicine for the same issue?

Dagla contains the active ingredient Itopride hydrochloride, which is designated as a prescription-only medication. The requirement for a prescription is due to its specific pharmacological class and the need for medical supervision and monitoring to manage its actions and potential safety profile.

---

Q: Is Dagla known to cause weight changes?

Based on official adverse event reporting in regulatory documents, changes in body weight or weight gain are not commonly listed as reported side effects for this medication.

---

Q: What happens if I miss a scheduled dose of Dagla?

Official regulatory documents contain specific instructions for managing a missed dose. These instructions provide guidance on when to take a dose and when to skip it, and they advise against taking two doses at one time.

---

Q: How long does Dagla stay in your system after you stop taking it?

Regulatory pharmacokinetics data indicates that the elimination half-life of the active ingredient is approximately 6 hours. This means that half the concentration of the substance is removed from the body in that time, with complete elimination occurring over multiple half-lives.

---

Q: Does Dagla interact with common pain relievers like ibuprofen?

Official product labeling does not mention specific interactions with common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. However, the drug's mechanism of accelerated gastric emptying is described as having the potential to influence the absorption of other oral drugs taken concurrently.

---

Q: What if I forget if I already took my Dagla dose?

Official regulatory guidance describes the actions to be taken when a dose is forgotten or if the patient is unsure if a dose was taken. This guidance specifically addresses when a dose should be skipped and advises against taking two doses at once.

---

Q: Is there a generic version of Dagla available?

The active ingredient, Itopride hydrochloride, is recognized globally and is available under generic names in several countries. The availability of a specific generic version may depend on the regulatory status and market in your location.

---

Q: Can Dagla be taken with common vitamin supplements?

Official product labeling does not specifically address interactions with vitamins or mineral supplements. Regulatory information indicates that there is a potential for accelerated gastric emptying to influence the absorption of other oral products, which includes supplements.

---

Q: Does alcohol consumption affect how Dagla works?

The official interaction between alcohol and the active ingredient is generally noted as unknown in regulatory safety information. The lack of specific data requires professional clarification regarding the consumption of alcohol while using this medicine.

---

Q: What should I do if Dagla does not seem to be working for me?

Official instructions state that the medicine should not be discontinued unless a doctor gives specific instruction, even if a lack of response is perceived. Perceived lack of effect is typically a factor for a subsequent clinical assessment.

---

Q: Are there any known interactions between Dagla and herbal products?

Official product labeling does not typically contain specific information about interactions with herbal products. However, the medicine's action can accelerate gastric emptying, which has the potential to influence the absorption of any other oral products, including herbal supplements.

---

Q: Can Dagla be used by people with high blood pressure?

Official regulatory documents do not list high blood pressure (hypertension) as a condition that is absolutely prohibited (a contraindication) or one that requires dose adjustment or special caution.

---

Q: How does Dagla compare to older treatments for the same condition?

Dagla's active ingredient, Itopride, is distinguished by its dual mechanism of action, being classified as both a dopamine D2 receptor antagonist and an acetylcholinesterase inhibitor. This combined action is the basis of its pharmacological identity within the therapeutic class of prokinetic agents.

---

Q: What kind of research is currently being done on Dagla?

Clinical trial records indicate that ongoing studies are focused on evaluating the effects of the drug in functional dyspepsia and other gastrointestinal conditions. This aligns with the medicine's official use as a prokinetic agent.

---

Q: If I have a mild side effect from Dagla, should I stop using it?

Official instructions state that the medicine should not be discontinued unless a doctor gives specific instruction, even in the event of mild side effects. Persistent side effects are factors that may be reviewed during a professional consultation.

---

Q: Does Dagla interact with birth control pills?

Official product labeling does not mention a specific drug-drug interaction with oral contraceptives. However, the mechanism of accelerated gastric emptying is described as having the potential to influence the absorption of any oral drugs. This potential influence is a documented general consideration for all oral medications.

---

Q: Is Dagla affected by grapefruit or grapefruit juice?

Regulatory safety information contains an advisory statement regarding grapefruit or grapefruit juice. This is due to the potential for it to influence the concentration of the medicine in the body and possibly increase the risk of adverse effects.

---

Q: Why is Dagla considered a prescription-only medication?

The prescription status is primarily due to its classification as a prokinetic agent and the need for medical supervision and monitoring. Its use is subject to medical oversight because of the known contraindications and potential side effects, such as a rise in prolactin levels (hyperprolactinemia).

---

Q: Is Dagla approved in other countries besides the US?

Yes, official regulatory documentation and clinical trial data reference the medicine being marketed and used in several international regions, including countries in Asia and parts of Eastern Europe.

The official regulatory labeling for Dagla (dapagliflozin/metformin extended-release) establishes specific conditions to maintain the product’s quality and ensure safety.

Classification	Requirement
Storage Temperature	Store at controlled room temperature (20 C–25 C or 68 F–77 F).
Environmental Protection	Keep away from excess heat, moisture, and direct light; must not be frozen.
Container & Safety	Keep the medicine in its container, which must be tightly closed and stored out of the reach of children.
Handling Restriction	The tablets must be swallowed whole and must never be crushed, cut, or chewed.

For disposal, the product should not be thrown into household waste or flushed down the toilet. Unused or expired medication should be disposed of by following local or national regulations, often through a regulated drug take-back program.